Objective To analyze the predictive value of a logistic model of clinical characteristics on the prostate symptom improvement after transurethral resection of the prostate (TURP) for benign prostatic hyperplasia. Methods A retrospective analysis was used to include 1, 100 patients with benign prostatic hyperplasia admitted to the hospital from January 2020 to January 2025. The symptom improvement status after treatment was evaluated using the International Prostate Symptom Score (IPSS). According to the IPSS reduction value (ΔIPSS) after 6 months of treatment, the symptoms improvement was defined as ΔIPSS≥3 points, and non-improvement was defined as ΔIPSS<3 points or IPSS elevation.1 100 patients were categorized into symptom improvement group (n=984) and symptom non-improvement group (n=116). Univariate analysis and Logistic regression analysis were utilized to analyze the risk factors of patients. Receiver operating characteristic (ROC) curve was drawn to analyze the predictive value of clinical characteristics on prostate symptom improvement. Results The results of the single-factor analysis showed that age, prostate volume, postvoid residual urine (PVR), average urinary flow rate (Qave), maximum urinary flow rate (Qmax), International Index of Erectile Function-5 (IIEF-5), and prostate-specific antigen (PSA) were all factors influencing the improvement of symptoms after transurethral resection of the prostate (TURP) (P<0.05); the results of the logistic regression analysis showed that prostate volume, PVR, and PSA were independent risk factors for the improvement of prostate symptoms after TURP, while Qave, Qmax, and IIEF-5 were protective factors (P<0.05); the ROC curve indicated that the area under the curve (AUC), sensitivity, and specificity of the combined prediction were 0.989, 90.0%, and 99.1%, respectively, which were higher than those of other indicators when used for individual diagnosis (P<0.05). Conclusion The logistic model based on clinical characteristics can effectively predict the prostate symptom improvement after TURP.
Key words
benign prostatic hyperplasia /
transurethral resection of the prostate /
symptom improvement /
clinical characteristics
{{custom_sec.title}}
{{custom_sec.title}}
{{custom_sec.content}}
References
[1] IINFANTE HERNANDEZ S, GOMEZRIVAS J, MORENO SIERRA J.Benign prostatic hyperplasia[J]. Med Clin, 2024, 163(8): 407-414.
[2] PORTO JG, BHATIA AM, BHAT A, et al.Evaluating transurethral resection of the prostate over twenty years: a systematic review and meta-analysis of randomized clinical trials[J]. World J Urol, 2024, 42(1): 639.
[3] CHEN F, CHEN Y, ZOU Y, et al.Comparison of holmium laser enucleation and transurethral resection of prostate in benign prostatic hyperplasia: a systematic review and meta-analysis[J]. J Int Med Res, 2023, 51(8): 3000605231190763.
[4] ROBINSON C, HEPBURN A, TURNER RM, et al.The role of intra-operative void score during transurethral resection of prostate as a marker of efficacy: a feasibility study[J]. ANZ J Surg, 2022, 92(6): 1492-1497.
[5] SANTINI AJ, JAKARADDI CA, POLYDOROS F, et al.Validity of the international prostate symptoms score in predicting urinary retention after joint replacement[J]. J Orthop Surg, 2019, 27(3): 2309499019868670.
[6] Langan RC.Benign prostatic hyperplasia[J]. Prim Care, 2019, 46(2): 223-232.
[7] SCHOENTGEN N, MAROLLEAU J, DELAGE F, et al.Prospective four years of evaluation of erectile function after low-dose-rate prostate brachytherapy using baseline IIEF-5>16[J]. J Contemp Brachytherapy, 2019, 11(3): 195-200.
[8] 《中国高血压防治指南》修订委员会. 中国高血压防治指南2018年修订版[J]. 心脑血管病防治, 2019, 19(1): 1-44.
[9] INAMURA S, TERADA N.Chronic inflammation in benign prostatic hyperplasia: pathophysiology and treatment options[J]. Int J Urol, 2024, 31(9): 968-974.
[10] AMU OC, AFFUSIM EA, NNADOZIE UU, et al.Outcome of transurethral resection of the prostate (TURP) using 5% dextrose water as irrigant[J]. Niger J Clin Pract, 2023, 26(10): 1568-1574.
[11] ZHENG Z, WU Z, LI K, et al.Incidence and risk factors of venous thromboembolism in patients after transurethral resection of the prostate (TURP)[J]. Front Surg, 2022, 8: 744244.
[12] 兰孝达, 韩佳凝, 姜瑞, 等. 高龄患者接受经尿道前列腺增生手术后围术期并发症的危险因素分析[J]. 微创泌尿外科杂志, 2025, 14(1): 38-45.
[13] LIU S, LIU H, YAO H, et al.A systematic review and meta-analysis of efficacy and safety comparing greenlight laser vaporization with transurethral resection of the prostate for benign prostatic hyperplasia with prostate volume less than 80ml[J]. Lasers Med Sci, 2023, 38(1): 133.
[14] RUBILOTTA E, BALZARRO M, GUBBIOTTI M, et al.Role of bladder emptying on outcomes of transurethral resection of the prostate[J]. Urology, 2023, 175: 25-28.
[15] 古晋鹏, 冯振宇, 许鹤馨, 等. 全逆时针两叶法铥激光前列腺剜除术治疗良性前列腺增生症的疗效及安全性[J]. 微创泌尿外科杂志, 2024, 13(6): 388-393.
[16] 余洪波, 关翰, 李聪, 等. 钬激光剜除术治疗良性前列腺增生症的疗效及其对血清前列腺特异性抗原和勃起功能的影响[J]. 川北医学院学报, 2025, 40(1): 41-44.
[17] 王超, 张峰波, 杨立军, 等. 柱状水囊前列腺扩开术对良性前列腺增生患者国际勃起功能指数的影响[J]. 中国性科学, 2022, 31(10): 35-38.
[18] GOBLER C, PFANDER F, HAAS M, et al.Risk factors for bladder neck contracture after transurethral resection of the prostate[J]. Prostate, 2023, 83(11): 1020-1027.
[19] OTTAIANO N, SHELTON T, SANEKOMMU G, et al.Surgical complications in the management of benign prostatic hyperplasia treatment[J]. Curr Urol Rep, 2022, 23(5): 83-92.
[20] MOROZOV AM, SHPIKINA A, et al.Comparison of EEP and TURP long-term outcomes: systematic review and meta-analysis[J]. World J Urol, 2023, 41(12): 3471-3483.